Hideko Isozaki

Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i> -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion

Zofia Piotrowska, Hideko Isozaki, Jochen K. Lennerz et al. · Cancer Discovery · 2018 · 445 citations

Medicine, Oncology, Pharmacology +17

Therapy-induced APOBEC3A drives evolution of persistent cancer cells

Hideko Isozaki, Ramin Sakhtemani, Ammal Abbasi et al. · Nature · 2023 · 145 citations · Full text

Medicine, Cancer Biology, Molecular Genetics +12

Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases

Hideko Isozaki, Eiki Ichihara, Nagio Takigawa et al. · Cancer Research · 2016 · 128 citations · Full text

Medicine, Oncology, Pharmacology +14

Genetic alterations of candidate tumor suppressor ING1 in human esophageal squamous cell cancer.

L. Chen, N. Matsubara, Teruo Yoshino et al. · PubMed · 2001 · 79 citations

Medicine, Genetics, Molecular Genetics +17

MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC

Naoki Haratake, Hiroki Ozawa, Yoshihiro Morimoto et al. · Journal of Thoracic Oncology · 2023 · 45 citations · Full text

Medicine, Oncology, Pharmacology +17